10-Q: Nuo Therapeutics Q1 2026: Revenue Surges, Net Loss Narrows

Nuo Therapeutics reports a significant revenue increase in Q1 2026 driven by product sales and distribution fees, though the company continues to face substantial doubt regarding its ability to continue as a going concern.

Summary

• Nuo Therapeutics reported total revenues of $1.302 million for the first quarter ended March 31, 2026, a substantial increase from $484,381 in the same period of 2025.
• Product sales reached $1.224 million, up from $484,381 in Q1 2025, boosted by increased Aurix product sales and revenue from the Smith+Nephew private label agreement.
• Distribution fee revenue from the amended Smith+Nephew agreement contributed $77,941 in Q1 2026.
• Gross profit increased to $849,727 from $363,360 in the prior year's quarter, with a gross margin of 65% in Q1 2026 compared to 75% in Q1 2025.
• Operating expenses rose to $1.296 million from $1.108 million in Q1 2025, primarily due to increased compensation, benefits, and sales commissions.
• The net loss for the quarter was $618,466, an improvement from a net loss of $746,128 in Q1 2025.
• The company has $263,827 in cash and cash equivalents as of March 31, 2026, and continues to face substantial doubt about its ability to continue as a going concern due to recurring losses and limited cash resources.
• The company secured $1 million in funding through secured notes payable in January 2026, with an additional $600,000 available under certain conditions.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant revenue growth being overshadowed by persistent net losses, a precarious cash position, and a strong warning about the company's ability to continue as a going concern.

Positives

• Total revenues increased by approximately 153% to $1.302 million in Q1 2026 compared to $484,381 in Q1 2025.
• Product sales significantly increased to $1.224 million in Q1 2026 from $484,381 in Q1 2025.
• Gross profit improved to $849,727 in Q1 2026 from $363,360 in Q1 2025.
• Net loss narrowed to $618,466 in Q1 2026 from $746,128 in Q1 2025.
• The company secured $1 million in secured notes payable funding in January 2026.
• The distribution agreement with Smith+Nephew is contributing revenue through product sales and distribution fees.

Negatives

• The company has an accumulated deficit of approximately $35.4 million as of March 31, 2026.
• Stockholders' deficit was approximately $1.4 million as of March 31, 2026.
• Cash and cash equivalents were only $263,827 as of March 31, 2026.
• The company's current resources and projected revenue are insufficient to support operations for the next 12 months, leading to substantial doubt about its ability to continue as a going concern.
• Gross margin decreased to 65% in Q1 2026 from 75% in Q1 2025, partly due to lower margins on private label centrifuge devices sold to Smith+Nephew.
• Operating expenses increased by approximately $188,000 in Q1 2026 compared to Q1 2025.
• The company has identified material weaknesses in its internal control over financial reporting due to a lack of sufficient accounting and financial reporting resources.

Risks

• The company has recurring losses and limited cash resources, raising substantial doubt about its ability to continue as a going concern.
• The company requires additional capital and may not be able to obtain it on satisfactory terms or at all.
• Any future equity financing may cause substantial dilution to existing stockholders.
• Additional debt financing may impose onerous financial covenants and restrict business operations.
• The company relies on single-source suppliers for certain product components, including an exclusive supplier for bovine thrombin.
• The company's ability to successfully market and sell the Aurix System and realize benefits from the Smith+Nephew distribution agreement is subject to various risks.
• The company has provided Smith+Nephew with notification and negotiation rights regarding potential business combinations or asset disposals, which could impact strategic flexibility.
• The company has material weaknesses in its internal control over financial reporting, which could lead to misstatements in financial reporting.

Future Outlook

The company expects revenues to continue growing in the future, driven by increased Aurix product sales and the Smith+Nephew distribution agreement. However, the company acknowledges substantial doubt about its ability to continue as a going concern and requires additional capital for future operations. The availability of up to $600,000 in additional funding under the Loan Agreement is subject to closing conditions.

Management Comments

• Management believes that the company's current resources and projected revenue are insufficient to support operations for the next 12 months, leading to substantial doubt about its ability to continue as a going concern.
• Management states that any equity financing may cause further substantial dilution to stockholders and could involve the issuance of securities with rights senior to common stock.
• Management believes that the ultimate resolution of pending legal matters will not have a material adverse effect on the company's financial position, results of operations, or cash flows.
• Management concluded that disclosure controls and procedures were not effective due to material weaknesses in internal control over financial reporting.

Industry Context

StockSavvy.ai notes that Nuo Therapeutics operates in the advanced wound care market, which was estimated at $10.8 billion globally in 2021. The company's focus on autologous PRP products like Aurix aligns with a growing trend in regenerative medicine. However, the company's financial performance and going concern issues highlight the challenges of commercializing novel therapies in a competitive and capital-intensive industry.

Comparison to Industry Standards

• Nuo Therapeutics' gross margin of 65% in Q1 2026 is lower than the 75% achieved in Q1 2025, indicating potential pricing pressures or shifts in product mix. Industry benchmarks for medical device companies can vary widely, but maintaining healthy gross margins is crucial for profitability.
• The company's net loss of $618,466 in Q1 2026, while an improvement, still represents a significant operational deficit. Many early-stage medical device companies experience losses as they invest in R&D and market penetration. However, sustained losses without a clear path to profitability, as indicated by the going concern warning, are a significant concern compared to companies with more stable financial footing.
• The company's cash position of $263,827 is very low, especially considering its operating expenses. This contrasts sharply with larger, established medical device companies that typically maintain substantial cash reserves to fund operations, acquisitions, and research.
• The company's reliance on a single distribution partner (Smith+Nephew) for a significant portion of its private label revenue introduces concentration risk, a factor that investors scrutinize when comparing to more diversified companies.

Corporate Governance

Legal Proceedings

• There are currently no claims or actions pending against the company, the ultimate disposition of which could have a material adverse effect on its results of operations, financial condition, or cash flows.

Related Party Transactions

• Note payable - related party: $205,000 as of March 31, 2026.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future equity financings; ongoing concern about the company's going concern status.
• Creditors/Lenders: The company has secured notes payable, including from a related party and a director, with covenants and potential prepayment fees.
• Employees: Continued operations depend on securing additional funding; material weaknesses in financial reporting could impact confidence.
• Suppliers: The company relies on third-party manufacturers and has a single supplier for a critical reagent (bovine thrombin).

Next Steps

• Continue engaging and establishing relationships with providers treating chronic non-healing wounds.
• Broaden commercial customer relationships with wound care providers operating in private office settings.
• Continue engaging with hospitals and hospital systems regarding expanded POS 22 usage.
• Seek additional capital to fund operations.
• Implement further measures to improve internal control over financial reporting.

Key Dates

Recommendation

While revenue growth is positive, the persistent net losses, substantial doubt about the company's ability to continue as a going concern, and material weaknesses in internal controls present significant risks. The company's future is heavily dependent on its ability to secure additional financing on favorable terms. Investors should monitor the company's progress in securing capital and improving its financial reporting controls.

Keywords

Nuo Therapeutics, Form 10-Q, Quarterly Report, Medical Device, Wound Care, Aurix System, Platelet Rich Plasma, PRP, Smith+Nephew, Distribution Agreement, Financial Statements, Revenue, Net Loss, Going Concern, Capital Raise